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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 212 Revision 1 
(FGE.212Rev1): 
alpha,beta-Unsaturated alicyclic ketones and precursors from chemical 
subgroup 2.6 of FGE.19.1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate flavouring substances using the 
Procedure as referred to in the Commission Regulation (EC) No 1565/2000.  
In the present revision of FGE.212, FGE.212Rev1, there has been a reassessment of [FL-no: 02.083, 
02.101, 07.033, 07.035, 07.094, 07.098, 07.112, 07.129, 07.140, 07.172, 07.175, 07.196, 07.202 and 
07.255] for which there were a request for genotoxicity data in FGE.212. 
Flavouring Group Evaluation 212 (FGE.212) concerns 23 substances. The 23 substances correspond 
to subgroup 2.6 of FGE.19. Fifteen of these substances are alpha,beta-unsaturated alicyclic ketones 
[FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 7.146, 07.147, 07.172, 
07.175, 07.196, 07.202 and 07.255] and eight are precursors for such ketones [FL-no: 02.062, 02.083, 
02.101, 02.214, 09.143, 09.215, 09.821 and 09.870]. 
In the previous version of this Opinion, FGE.212, the Panel had expressed the following view. 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2010-01251, adopted on 25 November 2010. 
2  Panel members Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude 
Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, Detlef 
Wölfle. Correspondence: cef-unit@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, 
Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, 
Gerard Pascal, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard Nielsen for the 
preparatory work on this scientific Opinion. 
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d-Carvone [FL-no: 07.146] was found genotoxic in vitro. However, d-carvone was not carcinogenic in 
mice. Therefore, the Panel concluded that this substance together with the structurally related l-
carvone as well as carveol and the carvyl derivatives [FL-no: 02.062, 07.147, 09.143, 09.215 and 
09.870] could be evaluated through the Procedure.  
Isophorone [FL-no: 07.126 (3,5,5-trimethylcyclohex-2-en-1-one)] is genotoxic in vitro and since there 
is some evidence of carcinogenicity in male rats and equivocal evidence of carcinogenicity in male 
mice and since a non-threshold mechanism could not be excluded based on the data currently 
available, the Panel concluded that additional data are required for isophorone in order to clarify 
whether genotoxicity occurs in vivo and whether there is a threshold for the effects observed in the 
target organs in the long-term bioassays. Therefore, an in vivo Comet assay in F344/N rats covering 
these target organs is required in addition to an in vivo bone marrow assay with oral application.  
Due to structural similarities and lack of data at the time of evaluation in previous version of FGE.212, 
the remaining substances could not be evaluated through the Procedure [FL-no: 02.083, 02.101, 
02.214, 07.033, 07.035, 07.094, 07.098, 07.112, 07.129, 07.140, 07.172, 07.175, 07.196, 07.202, 
07.255 and 09.821]. Additional data on genotoxicity are requested for representative substances of this 
subgroup according to the Opinion of the Panel on Genotoxicity Test Strategy for Substances 
Belonging to Subgroups of FGE.19. 
In response to the Panel request expressed in FGE.212, the Flavouring Industry has submitted 
additional genotoxicity data. Based on these data the Panel could rule out the genotoxicity concern for 
isophorone and the substances structurally related to isophorone [FL-no: 02.083, 02.101, 07.035, 
07.098, 07.126, 07.129, 07.172, 07.175, 07.196, 07.202 and 07.255]. On the other hand, the Panel 
could not agree in the Industry argument that isophorone can be representative for the remaining 
substances for which the Panel requested additional genotoxicity data in FGE.212 [FL-no: 02.214, 
07.033, 07.094, 07.112, 07.140 and 09.821]. For these substances additional data are still requested. 
KEYWORDS 
alpha,beta-Unsaturated ketones, alicyclic ketones, flavouring substances, safety evaluation. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other flavouring substances in the EU. In application of that Regulation, a 
Register of flavouring substances used in or on foodstuffs in the Member States was adopted by 
Commission Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 
2009/163/EC (EC, 2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) 
and all substances are divided into 34 chemical groups. Substances within a group should have some 
metabolic and biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union list of flavouring substances for use in or 
on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being alpha,beta-unsaturated aldehydes or ketones and precursors which could give rise to such 
carbonyl substances via hydrolysis and/or oxidation (EFSA, 2008b). 
The alpha,beta-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The 
Panel noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The alpha, beta-unsaturated carbonyls were subdivided into 28 subgroups on the basis of structural 
similarity (EFSA, 2008b). In an attempt to decide which of the substances could go through the 
Procedure, a (quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of 
these substances was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-
MultiCASE Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these alpha,beta-unsaturated carbonyls. Therefore, the 
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and 
decided not to take substances through the Procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni & Netzeva, 
2007a; Benigni & Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov 
et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as well as 
data on carcinogenicity for several substances. The Panel decided that 11 subgroups (1.1.2, 1.1.3, 
1.1.4, 2.4, 2.6, 2.7, 3.1, 3.3, 4.1, 4.2 and 4.4) (EFSA, 2008b) should be further examined to determine 
whether evaluation through the Procedure is feasible. Corresponding to these 11 subgroups 11 
Flavouring Group Evaluations (FGEs) were established, FGE.201, 202, 203, 210, 212, 213, 214, 216, 
217, 218 and 220. If the Panel concludes for any substances in these 11 FGEs that they cannot be 
evaluated using the Procedure then it has to be decided if there is a safety concern for certain 
substances or if additional data are required in order to finalise the evaluation. If the Panel concludes 
that a genotoxic potential can be ruled out for the substances they will be merged with structurally 
related substances in other FGEs and evaluated using the Procedure. 
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HISTORY OF EVALUATION 
In FGE.212 the Panel concluded that additional genotoxicity data were required for isophorone [FL-
no: 07.126] and due to structural similarities and lack of data, the following substances could presently 
not be evaluated through the Procedure [FL-no: 02.083, 02.101, 02.214, 07.033, 07.035, 07.094, 
07.098, 07.112, 07.129, 07.140, 07.172, 07.175, 07.196, 07.202, 07.255 and 09.821].  
 
Additional data on genotoxicity were requested for representative substances (EFSA, 2008bc) of this 
subgroup according to the Opinion of the Panel on the Genotoxicity Test Strategy for Substances 
Belonging to Subgroups of FGE.19 (EFSA, 2008bb). 
Representative substances for subgroup 2.6 of FGE.19 (EFSA, 2008bc) 
FL-no  
JECFA-no  
Subgroup  EU Register name  Structural formula  Comments  
02.214 
1866 
2.6  Vetiverol 
 
HO
 
Representative: 2,6-
Dimethyl-9-(1-
methylethylidene)- 
bicyclo[5.3.0]dec-2-en-4-
one (not in register) or its 
precursor [02.214]. 
07.112 
1105 
2.6 3-Methyl-2-cyclopenten-1-one O Representative 
07.126 
1112 
2.6 3,5,5-Trimethylcyclohex-2-en-1-
one 
O
 
Representative 
An in vivo Comet assay in 
F344/N rats covering the 
target organs in the 
carcinogenicity studies on 
[07.126] and an in vivo 
bone marrow assay with 
oral application  
 
 
The present Flavouring Group Evaluation 212, Revision 1 (FGE.212Rev1) includes the assessment of 
additional genotoxicity data submitted by Industry in reply to data request presented in FGE.212 for 
isophorone and structurally related substances. These new data are described and evaluated in Section 
4 in the present FGE. Sections 1-3 report the same information that was present in the earlier version 
of FGE.212. 
TERMS OF REFERENCE 
The European Commission requests the European Food Safety Authority to carry out risk assessment 
on the following 15 substances: p-Menth-1-en-3-ol [FL-no: 02.083], pin-2-en-4-ol [FL-no: 02.101], 
isojasmone [FL-no: 07.033], tetramethyl ethylcyclohexenone [FL-no: 07.035], 3-methyl-2-(pent-
2(cis)-enyl)cyclopent-2-en-1-one [FL-no: 07.094], 3-methylcyclohex-2-en-1-one [FL-no: 07.098], 3-
methyl-2-cyclopenten-1-one [FL-no: 07.112], isophorone (3,5,5-trimethylcyclohex-2-en-1-one) [FL-
no: 07.126], 3-methyl-5-propylcyclohex-2-en-1-one [FL-no: 07.129], 3-methyl-2-pentylcyclopent-2-
en-1-one [FL-no: 07.140], 4-isopropylcyclohex-2-en-1-one [FL-no: 07.172], p-menth-1-en-3-one [FL-
FGE Adopted by 
EFSA 
Link No. of 
Substances 
FGE.212 27 November 2008 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902780085.htm 
23 
FGE.212Rev1 November 2010  23 
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no: 07.175], pin-2-en-4-one [FL-no: 07.196], 2,6,6-trimethylcyclohex-2-en-1-one [FL-no: 07.202] and 
1-piperitone [FL-no: 07.255], in accordance with Commission Regulation (EC) No 1565/2000 by end 
of 2010. 
ASSESSMENT 
1. Presentation of the Substances in the Flavouring Group Evaluation 212 Revision 1 
1.1. Description 
The present Flavouring Group Evaluation 212, Revision 1 (FGE.212Rev1) concerns 23 substances, 
which are presented in Table 1. The 23 substances correspond to subgroup 2.6 of FGE.19 (EFSA, 
2008b). Fifteen of these substances are alpha,beta-unsaturated alicyclic ketones (alpha,beta-
unsaturation in the side chain) [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 
07.140, 7.146, 07.147, 07.172, 07.175, 07.196, 07.202 and 07.255] and eight are precursors for such 
ketones [FL-no: 02.062, 02.083, 02.101, 02.214, 09.143, 09.215, 09.821 and 09.870].  
A summary of their current evaluation status by the JECFA is given in Table 2 (JECFA, 1999a; 
JECFA, 2003a; JECFA, 2006a). 
The alpha,beta-unsaturated aldehyde and ketone structures are considered by the Panel to be structural 
alerts for genotoxicity (EFSA, 2008b). Accordingly the available data on genotoxic or carcinogenic 
activity for the 15 ketones in FGE.212 [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 
07.129, 07.140, 7.146, 07.147, 07.172, 07.175, 07.196, 07.202 and 07.255] and one ketone [2,6-
dimethyl-9-(1-methylethylidene)-bicyclo[5.3.0]dec-2-en-4-one (non Register substance)] correspon-
ding to the 23 substances in FGE.212, will be considered in this FGE. 
The Panel also noted that for one substance [FL-no: 07.033], the CASrn, name and chemical structure 
were not consistent (Table 1). Therefore a clarification is needed. 
The Panel has also taken into consideration the outcome of the predictions from five selected (Q)SAR 
models (Benigni & Netzeva, 2007a; Gry et al., 2007; Nikolov et al., 2007) on the 15 ketones FL-no: 
07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 7.146, 07.147, 07.172, 07.175, 
07.196, 07.202 and 07.255] and the one non-register ketone [2,6-dimethyl-9-(1-methylethylidene)-
bicyclo[5.3.0]dec-2-en-4-one in this FGE. The 15 ketones and the one non-Register ketone as well as 
their (Q)SAR predictions are shown in Table 3. 
2. Toxicity 
2.1. (Q)SAR Predictions 
In Table 3 the outcomes of the (Q)SAR predictions for possible genotoxic activity in five in vitro 
(Q)SAR models (ISS Local Model-Ames test, DTU-NFI MultiCASE-Ames test, -Chromosomal 
aberration test in Chinese hamster ovary cells (CHO), -Chromosomal aberration test in Chinese 
hamster lung cells (CHL), and -Mouse lymphoma test) are presented. 
Positive predictions have been obtained for six substances with the MultiCASE Mouse lymphoma 
model and for one of these substances also with the MultiCASE model on chromosomal aberrations. 
For the other substances, the predictions of the MultiCASE models were negative, equivocal or the 
substances were out of domain. All substances were out of domain in the ISS model. 
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2.2. Carcinogenicity Studies4  
Groups of 50 male and 50 female F344/N rats were administered isophorone (3,5,5-trimethylcyclohex-
2-en-1-one [FL-no: 07.126]) in corn oil by gavage at dose levels of 0 (controls),  250 or 500 mg/kg 
body weight (bw)/day, five times per week for 103 weeks. During the study the body weights of the 
high-dose male and female rats were slightly lower than those of the vehicle controls. The survival of 
high-dose male rats was significantly lower than that of the vehicle controls after week 96. Dosed male 
rats showed a variety of proliferative lesions of the kidney (tubular cell hyperplasia, 0/50, 1/50, 4/50; 
tubular cell adenoma, 0/50, 0/50, 2/50; tubular cell adenocarcinoma, 0/50, 3/50, 0/50; epithelial 
hyperplasia of the renal pelvis, 0/50, 5/50, 5/50). Dosed male rats also exhibited increased 
mineralisation of the medullary collecting ducts (1/50, 31/50, 20/50) and low-dose male rats showed a 
more severe nephropathy than is commonly seen in aging F344/N rats. Carcinomas of the preputial 
gland were significantly increased (P < 0.03) in high-dose male rats (0/50, 0/50, 5/50). With the 
exception of a moderate increase in nephropathy (21/50, 39/50, 32/50), female rats did not show 
chemically related increased incidences of neoplastic or non-neoplastic lesions (NTP, 1986d). 
Groups of 50 male and 50 female B6C3F1 mice were administered isophorone (3,5,5-
trimethylcyclohex-2-en-1-one [FL-no: 07.126]) in corn oil by gavage at dose levels of 0 (controls), 
250 or 500 mg/kg bw/day, five times per week for 103 weeks. During the study the body weights of 
the high-dose female mice were slightly lower than those of the vehicle controls. The survival of male 
mice was low, whereas there was a significant trend toward increased survival of dosed female mice 
relative to that of the vehicle controls. In high-dose male mice, isophorone exposure was associated 
with an increased incidence of hepatocellular adenomas and carcinomas (18/48, 18/50, 29/50) and of 
mesenchymal tumors of the integumentary system (fibroma, fibrosarcoma, neurofibrosarcoma, or 
sarcoma, 6/48, 7/50, 14/50). An increased incidence of lymphomas or leukemias was noted in low-
dose male mice (8/48, 18/50, 5/50). Coagulative necrosis (3/48, 10/50, 11/50) and hepatocytomegaly 
(23/48, 39/50, 37/50) were observed more frequently in the livers of dosed male mice than in vehicle 
controls. No compound-related neoplastic or non-neoplastic lesions associated with isophorone 
exposure were seen in female mice (NTP, 1986d). 
The Panel concluded that isophorone increased the incidences of renal tubular cell adenomas and 
adenocarcinomas and of carcinomas of the preputial gland in male rats but not in female rats. In male 
mice, but not in females, it produced increased incidences of hepatocellular adenomas and carcinomas, 
mesenchymal tumors in the integumentary system, and malignant lymphomas. 
The Panel agrees with the authors of the NTP report who concluded that “under the conditions of these 
2-year gavage studies, there was some evidence of carcinogenicity of isophorone in male F344/N rats 
as shown by the occurrence of renal tubular cell adenomas and adenocarcinomas in animals given 250 
or 500 mg/kg bw per day; carcinomas of the preputial gland were also observed at increased incidence 
in male rats given 500 mg/kg bw. There was no evidence of carcinogenicity in female F344/N rats 
given 250 or 500 mg/kg bw per day. For male B6C3F1 mice, there was equivocal evidence of 
carcinogenicity of isophorone as shown by an increased incidence of hepatocellular adenomas or 
carcinomas (combined) and of mesenchymal tumors in the integumentary system in animals given 500 
mg/kg bw per day and by an increase in malignant lymphomas in animals given 250 mg/kg bw per 
day. There was no evidence of carcinogenicity of isophorone in female B6C3F1 mice given 250 or 500 
mg/kg bw per day.” 
Groups of 50 male and 50 female B6C3F1 mice (7-week old) were administered 0, 375 or 750 mg/kg 
bw d-carvone [FL-no: 07.146] in corn oil by gavage, five days per week for 103 weeks. The mean 
body weights of dosed and control male and female mice were similar throughout most of the study. 
The survival of both the low-dose and the high-dose females were significantly greater than that of the 
controls. No differences in survival were observed between any groups of male mice. Atrophy of the 
                                                     
 
4 The data presented in Section 2.2 and Section 2.3 is cited from the previous version of the present FGE.212. 
These data are the basis for the conclusions in FGE.212 requesting additional genotoxicity data. 
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olfactory epithelium and hyperplasia of the underlying Bowman's glands occurred together with high 
incidence in either sex in both dosed groups. This effect was found due to a local effect of d-carvone 
caused by reflux of the gavage material when the gavage needle was withdrawn. No increases in 
tumour incidences were seen in mice administered d-carvone. The incidences of male mice with 
primary neoplasms and the total numbers of primary neoplasms were significantly lower in the dosed 
groups than in the vehicle controls (NTP, 1990b). 
The Panel concluded that d-carvone was not carcinogenic in mice under the study conditions. It agrees 
with the authors of the NTP report who concluded that “under the conditions of these 2-year gavage 
studies, there was no evidence of carcinogenic activity of d-carvone for male or female B6C3F1 mice 
administered 375 or 750 mg/kg, 5 days per week for 2 years.” 
Study validation and results are presented in Table 4. 
2.3. Genotoxicity Studies4 
In subgroup 2.6 there are studies available for four substances. For tetramethyl ethylcyclohexenone 
(mixture of isomers [FL-no: 07.035] one in vitro and one in vivo study have been evaluated. 
Seven in vitro and three in vivo studies are available for 3,5,5 trimethylcyclohex-2-en-1-one [FL-no: 
07.126] (isophorone). 
Three in vitro studies are available concerning d-carvone [FL-no: 07.146] and two in vitro studies 
concerning l-carvone [FL-no: 07.147]. 
Study validation and results are presented in Table 5 and 6. 
3,5,5 Trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) did not induce gene mutations in 
bacteria but it induced mutations in mammalian cells in a mouse lymphoma TK assay in the absence 
of metabolic activation (it was not tested in the presence of metabolic activation) (NTP, 1986d). No 
mutations in the MLTK assay were observed in a study of O’Donoghue et al. (O’Donoghue et al., 
1988) at comparable concentrations. Isophorone induced chromosomal aberrations in Chinese hamster 
lung fibroblasts with and without metabolic activation (Matsuoka et al., 1996) and sister chromatid 
exchanges (SCE) in CHO cells without metabolic activation (Gulati et al., 1989). Chromosomal 
aberrations have not been observed in two other studies (Gulati et al., 1989; NTP, 1986d); however, 
the validity of the results was limited because the types of aberrations were not reported. Isophorone 
did not induce unscheduled DNA synthesis (UDS) in rat hepatocytes in vitro. In vivo, isophorone was 
tested negative in a sex-linked recessive lethal mutation assay in Drosophila (Foureman et al., 1994) 
and in two micronucleus assays in mice (McKee et al., 1987; O’Donoghue et al., 1988). However, the 
Drosophila assay has only limited relevance and the micronucleus assays were of limited validity. 
Negative results were also observed with tetramethyl ethylcyclohexenone [FL-no: 07.035] in bacteria, 
in a sex-linked recessive lethal mutation assay in Drosophila (Wild et al., 1983) and in a mouse 
micronucleus assay (Wild et al., 1983); however, there was a mixture of isomers tested and the studies 
were only of limited validity.  
d-Carvone [FL-no: 07.146] was not mutagenic in bacteria but induced SCE and chromosomal 
aberrations in CHO cells in the presence and absence of metabolic activation, respectively (NTP, 
1990b). 
Flavouring Group Evaluation 212, Revision 1
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2.4. Conclusion on Genotoxicity and Carcinogenicity5 
The Panel concluded that 3,5,5 trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) is 
genotoxic in vitro while a final conclusion on the genotoxicity in vivo could not be drawn based on the 
data available. It is carcinogenic in male rats and male mice. It was also predicted to be genotoxic in 
one of the four MultiCASE models (while it was out of domain in the ISS model). 
d-Carvone [FL-no: 07.146] is genotoxic in vitro while no in vivo data were available. d-Carvone, was 
not carcinogenic in mice and was predicted to be non-genotoxic in the four MultiCASE models (while 
it was out of domain in the ISS model). No data are available on l-carvone. However, in vivo studies in 
humans show that the metabolism of ingestion-correlated amounts of d- or l-carvone occurs via a 
major oxidative pathway of the isopropylene side chain yielding diol and two carboxylic acids, 
irrespective of the stereochemical difference between the two parent isomers of carvone (Engel, 2001). 
Accordingly, the results for d-carvone can be used for l-carvone as well. 
The negative results reported from in vivo studies on the genotoxicity of tetramethyl 
ethylcyclohexenone [FL-no: 07.035] were only of limited validity. 
3. Conclusion5 
The present Flavouring Group Evaluation 212 (FGE.212) concerns 23 substances. The 23 substances 
correspond to subgroup 2.6 of FGE.19. Fifteen of these substances are alpha,beta-unsaturated alicyclic 
ketones [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 7.146, 07.147, 
07.172, 07.175, 07.196, 07.202 and 07.255] and eight are precursors for such ketones [FL-no: 02.062, 
02.083, 02.101, 02.214, 09.143, 09.215, 09.821 and 09.870]. 
d-Carvone [FL-no: 07.146] was found genotoxic in vitro. However, d-carvone was not carcinogenic in 
mice. Therefore, the Panel concluded that this substance together with the structurally related l-
carvone as well as carveol and the carvyl derivatives [FL-no: 02.062, 07.147, 09.143, 09.215 and 
09.870] could be evaluated through the Procedure.  
Isophorone [FL-no: 07.126 (3,5,5-trimethylcyclohex-2-en-1-one)] is genotoxic in vitro and since there 
is some evidence of carcinogenicity in male rats and equivocal evidence of carcinogenicity in male 
mice and since a non-threshold mechanism could not be excluded based on the data currently 
available, the Panel concluded that additional data are required for isophorone in order to clarify 
whether genotoxicity occurs in vivo and whether there is a threshold for the effects observed in the 
target organs in the long-term bioassays. Therefore, an in vivo Comet assay in F344/N rats covering 
these target organs is required in addition to an in vivo bone marrow assay with oral application.  
Due to structural similarities and lack of data, the remaining substances cannot presently be evaluated 
through the Procedure [FL-no: 02.083, 02.101, 02.214, 07.033, 07.035, 07.094, 07.098, 07.112, 
07.129, 07.140, 07.172, 07.175, 07.196, 07.202, 07.255 and 09.821]. Additional data on genotoxicity 
are requested for representative substances of this subgroup according to the Opinion of the Panel on 
the Genotoxicity Test Strategy for Substances Belonging to Subgroups of FGE.19 (EFSA, 2008bb). 
4. Data submitted from Industry in reply to genotoxicity data requested in FGE.212 
Honma et al. (Honma et al., 1999a; Honma et al., 1999b) found that isophorone did not clearly induce 
mutations in the mouse lymphoma assay (MLA) following 3 hours treatments, but observed that it was 
mutagenic after 24 hours treatments in the absence of S9. Although only graphs are plotted, it seems 
                                                     
 
5 The conclusions in Section 2.4  and Section 3 are cited from the previous version of the present FGE, 
FGE.212. This conclusion is the basis for the request of additional genotoxicity data in FGE.212. 
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that increases in mutation frequency (MF) that exceeded the Global Evaluation Factor (GEF) occurred 
at around 1250‐1500 μg/ml where toxicity (by relative survival) reached 70‐90 %. 
The NTP conducted a mouse bone marrow chromosomal aberration (CA) study on isophorone. 
Groups of 8 male B6C3F1 mice (larger group sizes than required by OECD) were dosed i.p. with 
isophorone at 125, 250 and 500 mg/kg bw. The standard protocol for in vivo CA is not given on the 
NTP website. However, based on Shelby and Witt (Shelby & Witt, 1995), animals should have been 
sampled at 17 hours and, if negative, also at 36 hours. The data on the NTP website are only for bone 
marrow sampled at 36 hours. It is therefore possible that a 17 hours sample was also taken, and found 
to be negative, but the data have not been posted. Fifty cells per animal were scored for CA and no 
increases in CA were seen. No measures of toxicity were recorded, but i.p. dosing should have 
guaranteed systemic exposure. The control CA frequency was normal (2.75 %) and the positive 
control (dimethylbenzanthracene) produced a significant response in CA frequency.  
A DNA binding study was conducted in which F344‐rats and B6C3F1‐mice (the strains used in the 
NTP carcinogenicity study) were exposed to isophorone (Thier et al., 1990). Animals of both sexes 
were dosed once or five times by gavage with 500 mg/kg bw of unlabelled isophorone spiked with 
[1,3,5‐14C]‐isophorone (specific activity: 52 mCi per mmol, 1.92 GBq per mmol). An additional group 
of acute dosed male rats received undiluted 14C‐isophorone for increased sensitivity. Rats and mice 
were maintained for 24 hours in closed metabolic cages. Twenty four hours after exposure, livers and 
kidneys (the tumour target tissues) were removed from the animals. DNA was isolated through 
hydroxyapatite chromatography and radioactivity was measured by liquid scintillation counting. No 
positive controls were included. Also no untreated controls were included, but, except for the liver 
sample of one mouse in the five times dose group, radioactivity values were within 2σ of background 
(6 dpm). Radioactivity values therefore did not indicate significant attachment of radioactivity to 
DNA. From these results it can be concluded that neither isophorone nor its metabolites bind 
covalently to DNA. 
In addition, a report by Morishita et al. (Morishita et al., 1997b) submitted to EPA (EPA, 1997), is 
relevant and appears to have been previously submitted only as an abstract. This study was designed to 
investigate whether isophorone and/or α2μ‐globulin6 might be involved in the induction of preputial 
gland tumours in F‐344 rats (10/sex/dose group). A series of experiments was performed in order to 
study several parameters including: 
• binding of isophorone to DNA of kidney and preputial gland. Groups of 10 male rats were dosed 
by gavage with 500 mg/kg of [14C]‐isophorone (specific activity 14.65 mCi/mmol; 100 
μCi/animal). Positive control animals were dosed with 3H‐labeled methyl nitrosourea. 
• DNA adduct detection by 32P‐postlabeling in young adult male and female rats (7 per group) 
dosed by gavage with 0, 250 or 500 mg/kg isophorone for five days. 
Extraction of preputial gland and kidney DNA from rats treated with single 500 mg/kg labeled doses 
yielded no evidence of isophorone binding to DNA, whereas the positive control showed significant 
binding to DNA of preputial gland and kidney. These negative results with isophorone were confirmed 
in the 32P ‐postlabeling assays.  
In addition Industry has also asked whether the information submitted for isophorone, (cyclohexenyl 
derivative), could also be applied to evaluate the genotoxic potential of the five-carbon membered ring 
substances (i.e. cyclopentenyl derivatives) in subgroup 2.6 (letter of EFFA to EFSA, dated 14/4-2010). 
This request was supported by the argumentation that there is structural resemblance with respect to 
steric hindrance around the alpha,beta-unsaturated double bond. In addition, Industry argued that the 
                                                     
 
6 Since interaction with α2μ-glubulin is not of direct relevance for the evaluation of genotoxic potential, this 
information is omitted from this study summary. 
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π-conjugation systems in these molecules is very nearly planar and that therefore the reactivity and 
genotoxic potentials of the five- and six-membered ring systems would be similar. No further data 
were provided to substantiate this argumentation.  
5. Discussion of the additional data 
Conflicting results were reported in two valid studies with the mouse lymphoma assay (MLA): one 
negative (O’Donoghue et al., 1988) and one positive (NTP, 1986d) at comparable concentrations. 
Mixed results were also reported in two studies of limited validity: one negative (Honma et al., 1999a) 
and one positive (Honma et al., 1999b). Another negative result was reported in a study (McKee et al., 
1987), the validity of which cannot be evaluated. In the light of the clearly negative results in two 
valid bacterial gene mutation tests (Ames test) and in a valid Sex Linked Recessive Lethal Mutations 
test (SLRL) in Drosophila, and taking into account the lack of specificity and high sensitivity of the 
MLA, overall the results presently available are considered of questionable relevance. The Panel 
agrees that isophorone demonstrates some genotoxic activity in vitro but that the new data demonstrate 
lack of clastogenicity in vivo. In addition, the new DNA-binding data from two separate studies 
provide convincing evidence that isophorone does not induce tumours via a genotoxic mechanism. On 
the basis of these data it may be argued that there is no need to perform further in vivo genotoxicity 
studies such as the Comet assay or bone marrow micronucleus test. Thus, based on the data available 
the Panel concluded that there is no concern with respect to genotoxicity of isophorone.  
6. Conclusion 
Since based on the additional information the concern for the genotoxic potential for isophorone has 
been alleviated, a genotoxic potential can also be ruled out for the other six-carbon members of 
subgroup 2.6 related to isophorone [FL-no: 02.083, 02.101, 07.035, 07.098, 07.126, 07.129, 07.172, 
07.175, 07.196, 07.202 and 07.255]. 
The Panel also concluded that isophorone can only be considered as representative for the six-carbon 
ring members of subgroup 2.6. The argumentation of Industry to expand this conclusion also to the 
cyclopentenyl derivatives in this subgroup [FL-no: 07.033, 07.094, 07.112 and 07.140] was 
considered too limited, given the lack of support from experimental data. Therefore, additional 
genotoxicity tests are still required for the representative substance [FL-no: 07.112] already chosen by 
the Panel. Alternatively, a more thorough explanation (physico-chemical parameters; experimental 
underpinning) of the proposed similar reactivity of six- and five-membered ring substances should be 
provided by Industry. Also for the seven-membered ring substance [FL-no: 02.214] (also covering 
[FL-no: 09.821]) additional data on genotoxicity are still required. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 212 (JECFA, 1999A; JECFA, 2003A; 
JECFA, 2006A) 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 212 (JECFA, 1999a; JECFA, 2003a; JECFA, 2006a) 
FL-no 
JECFA- no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
02.062 
381 
Carveol 
OH
2247 
2027 
99-48-9 
Liquid 
C10H16O    
152.24 
 
Freely soluble 
226-227 
 
IR 
96 % 
1.493-1.497 
0.947-0.953 
02.083 
434 
p-Menth-1-en-3-ol 
OH
3179 
10248 
491-04-3 
Liquid 
C10H18O   
154.25 
 
 
232 
 
NMR 
97 % 
1.4762 (25C) 
0.930-0.936 
02.101 
1404 
Pin-2-en-4-ol 
OH
3594 
10304 
473-67-6 
Solid 
C10H16O 
152.24 
Very slightly soluble 
Soluble 
n.a. 
63-67 
NMR 
95 % 
n.a. 
n.a. 
02.214 
 
Vetiverol 
HO
4217 
10321 
89-88-3 
Solid 
C15H24O 
220.35 
Practically insoluble or 
insoluble 
Freely soluble 
n.a. 
69 
NMR 
95 % 
n.a. 
n.a. 
07.033 
1115 
Isojasmone   6) O
+
O
3552 
167 
11050-62-7 
Liquid 
C11H18O 
166.26 
 
 
144 (13 hPa) 
 
NMR 
95 % 
1.472-1.477 
0.917-0.924 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 212 (JECFA, 1999a; JECFA, 2003a; JECFA, 2006a) 
FL-no 
JECFA- no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
07.035 
1111 
Tetramethyl ethylcyclohexenone 
(mixture of isomers) 
OO
29 % 68 %
+
3061 
168 
17369-60-7 
Liquid 
C12H20O 
180.29 
 
 
113-115 
 
NMR 
97 % 
1.485-1.490 
0.927-0.934 
07.094 
1114 
3-Methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-one 
O 3196 
11786 
488-10-8 
Liquid 
C11H16O 
164.25 
 
 
248 
 
NMR 
98 % 
1.495-1.501 
0.942-0.948 
07.098 
1107 
3-Methylcyclohex-2-en-1-one O 3360 
11134 
1193-18-6 
Liquid 
C7H10O 
110.16 
 
 
199-200 
 
NMR 
98 % 
1.490-1.498 
0.967-0.972 
07.112 
1105 
3-Methyl-2-cyclopenten-1-one O 3435 
11137 
2758-18-1 
Liquid 
C6H8O 
96.12 
 
 
74 (20 hPa) 
 
NMR 
98 % 
1.485-1.491 
0.968-0.975 
07.126 
1112 
3,5,5-Trimethylcyclohex-2-en-1-
one 
O 3553 
11918 
78-59-1 
Liquid 
C9H14O 
138.21 
 
 
213-215 
 
NMR 
97 % 
1.474-1.481 
0.919-0.927 
07.129 
1113 
3-Methyl-5-propylcyclohex-2-
en-1-one   6) 
O 3577 
 
3720-16-9 
Liquid 
C10H16O 
152.23 
 
 
242-244 
 
NMR 
95 % 
1.481-1.486 
0.924-0.928 
07.140 
1406 
3-Methyl-2-pentylcyclopent-2-
en-1-one 
O 3763 
 
1128-08-1 
Liquid 
C11H18O 
166.26 
Very slightly soluble 
Soluble 
79 (0.2 hPa) 
 
NMR 
99 % 
1.676-1.682 
0.911-0.917 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 212 (JECFA, 1999a; JECFA, 2003a; JECFA, 2006a) 
FL-no 
JECFA- no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
07.146 
380.1 
d-Carvone 
O
- 
- 
2244-16-8 
 
 
 
 
 
 
 
 
 
 
 
07.147 
380.2 
l-Carvone 
O
- 
- 
6485-40-1 
 
 
 
 
 
 
 
 
 
 
 
07.172 
1110 
4-Isopropylcyclohex-2-en-1-one   
6) 
O 3939 
11127 
500-02-7 
Liquid 
C9H14O 
138.21 
 
 
198 
 
NMR 
97 % 
1.481-1.490 
0.930-0.950 
07.175 
435 
p-Menth-1-en-3-one 
O
2910 
2052 
89-81-6 
Liquid 
C10H16O 
152.24 
Insoluble 
 
233-235 
 
IR 
94 % 
1.483-1.487 
0.929-0.934 
07.196 
 
Pin-2-en-4-one 
O
- 
11186 
80-57-9 
Liquid 
C10H14O 
150.22 
 
Freely soluble 
90 (16 hPa) 
 
 
95 % 
1.492-1.498 
0.975-0.981 
07.202 
 
2,6,6-Trimethylcyclohex-2-en-1-
one 
O - 
- 
20013-73-4 
Liquid 
C9H14O 
138.21 
Slightly soluble 
Freely soluble 
63 (16 hPa) 
 
MS 
95 % 
1.470-1.476 
0.924-0.930 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 212 (JECFA, 1999a; JECFA, 2003a; JECFA, 2006a) 
FL-no 
JECFA- no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
07.255 
1856 
l-Piperitone 
O
4200 
- 
4573-50-6 
Liquid 
C10H16O 
152.24 
Slightly soluble 
Freely soluble 
246 
 
MS 
99 % 
1.482-1.488 
0.929-0.935 
09.143 
383 
Carvyl propionate 
O
O
2251 
424 
97-45-0 
Liquid 
C13H20O2   
208.30 
Insoluble 
 
239 
 
IR 
98 % 
1.469-1.479 
0.942-0.962 
09.215 
382 
Carvyl acetate 
OO
2250 
2063 
97-42-7 
Liquid 
C12H18O2  
194.27 
Slightly soluble 
 
229 
 
IR 
98 % 
1.473-1.479 
0.964-0.970 
09.821 
 
Vetiveryl acetate 
O
O
- 
11887 
117-98-6 
Solid 
C17H26O2 
262.39 
 
Freely soluble 
406 
73 
 
95 % 
n.a. 
n.a. 
09.870 
 
Carvyl-3-methylbutyrate 
O
O
- 
- 
94386-39-7 
Liquid 
C15H24O2 
236.37 
Practically insoluble or 
insoluble 
Freely soluble 
343 
 
MS 
95 % 
1.462-1.468 
0.932-0.938 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
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TABLE 2: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
(JECFA, 1999A; JECFA, 2003A; JECFA, 2006A) 
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (JECFA, 1999a; JECFA, 2003a; JECFA, 
2006a) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) μg/capita/day) 
EU 
USA 
Class 2) 
JECFA Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
EFSA comments 
02.062 
381 
Carveol 
OH
9.5 
140 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212, genotoxic concern 
could be ruled out. Evaluated by JECFA 
before 2000. No EFSA consideration 
required. 
02.083 
434 
p-Menth-1-en-3-ol 
OH
0.012 
0.02 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out. Evaluated by 
JECFA before 2000. No EFSA 
consideration required. 
02.101 
1404 
Pin-2-en-4-ol 
OH
0.012 
0.2 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out.  
09.143 
383 
Carvyl propionate 
O
O
ND 
0.04 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212, genotoxic concern 
could be ruled out. Evaluated by JECFA 
before 2000. No EFSA consideration 
required. 
09.215 
382 
Carvyl acetate 
OO
4.0 
36 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212, genotoxic concern 
could be ruled out. Evaluated by JECFA 
before 2000. No EFSA consideration 
required. 
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (JECFA, 1999a; JECFA, 2003a; JECFA, 
2006a) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) μg/capita/day) 
EU 
USA 
Class 2) 
JECFA Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
EFSA comments 
09.870 
 
Carvyl-3-methylbutyrate 
O
O
0.0012 
 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212, genotoxic concern 
could be ruled out. 
07.033 
1115 
Isojasmone O
+
O
0.37 
0.01 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could not be ruled out. 
Additional genotoxicity data required for 
the representative [FL-no: 07.112]. 
07.035 
1111 
Tetramethyl ethylcyclohexenone 
(mixture of isomers) 
OO
29 % 68 %
+
7.8 
0.2 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out. 
07.094 
1114 
3-Methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-one 
O 13 
7.2 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could not be ruled out. 
Additional genotoxicity data required for 
the representative [FL-no: 07.112]. 
07.098 
1107 
3-Methylcyclohex-2-en-1-one O 0.012 
0.1 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out. 
 
07.112 
1105 
3-Methyl-2-cyclopenten-1-one O 0.06 
ND 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could not be ruled out. 
Additional genotoxicity data required for 
the representative [FL-no: 07.112]. 
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (JECFA, 1999a; JECFA, 2003a; JECFA, 
2006a) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) μg/capita/day) 
EU 
USA 
Class 2) 
JECFA Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
EFSA comments 
07.126 
1112 
3,5,5-Trimethylcyclohex-2-en-1-one O 4.6 
0.1 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out. 
07.129 
1113 
3-Methyl-5-propylcyclohex-2-en-1-
one 
O 0.097 
4.1 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out. 
07.140 
1406 
3-Methyl-2-pentylcyclopent-2-en-1-
one 
O 0.34 
0.2 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could not be ruled out. 
Additional genotoxicity data required for 
the representative [FL-no: 07.112]. 
07.172 
1110 
4-Isopropylcyclohex-2-en-1-one O 0.0012 
0.001 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out. 
07.175 
435 
p-Menth-1-en-3-one 
O
44 
10 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out. Evaluated by 
JECFA before 2000. No EFSA 
consideration required. 
07.255 
1856 
l-Piperitone 
O
490 
- 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, genotoxic 
concern could be ruled out. 
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (JECFA, 1999a; JECFA, 2003a; JECFA, 
2006a) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) μg/capita/day) 
EU 
USA 
Class 2) 
JECFA Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
EFSA comments 
07.146 
380.1 
d-Carvone 
O
2390 
9900 
Class II 
A3: Intake above threshold, A4: 
Not endogenous, A5: Adequate 
NOAEL exists 
4) Evaluated in FGE.212, genotoxic concern 
could be ruled out. Evaluated by JECFA 
before 2000. No EFSA consideration 
required. 
07.147 
380.2 
l-Carvone 
O
2390 
9900 
Class II 
A3: Intake above threshold, A4: 
Not endogenous, A5: Adequate 
NOAEL exists 
4) Evaluated in FGE.212, genotoxic concern 
could be ruled out. Evaluated by JECFA 
before 2000. No EFSA consideration 
required. 
07.202 
 
2,6,6-Trimethylcyclohex-2-en-1-one O 0.12 
- 
Class II 
No evaluation 
Not evaluated by 
JECFA 
Evaluated in FGE.212, genotoxic concern 
could be ruled out. 
02.214 
 
Vetiverol 
HO
0.011 
- 
Class II 
No evaluation 
Not evaluated by 
JECFA during 2000 to 
2008 
Evaluated in FGE.212, additional 
genotoxicity data required. 
07.196 
 
Pin-2-en-4-one 
O
15 
- 
Class II 
No evaluation 
Not evaluated by 
JECFA during 2000 to 
2008 
Evaluated in FGE.212, genotoxic concern 
could be ruled out. 
09.821 
 
Vetiveryl acetate 
O
O
0.011 
- 
Class II 
No evaluation 
Not evaluated by 
JECFA during 2000 to 
2008 
Evaluated in FGE.212, additional 
genotoxicity data required. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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TABLE 3: QSAR PREDICTIONS ON MUTAGENICITY IN FIVE MODELS FOR 16 KETONES FROM SUBGROUP 2.6 
Table 3: QSAR Predictions on Mutagenicity in Five Models for 16 Ketones from Subgroup 2.6 
FL-no 
JECFA-no 
Sub- 
group 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
ISS Local 
Model 
Ames Test 
TA100 
 
MultiCASE  
Ames test 
  
MultiCASE 
Mouse 
lymphoma test 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
MultiCASE 
Chromosoma
l aberration 
test in CHL 
Not in 
Register 
2.6 2,6-Dimethyl-9-(1-methylethylidene)-
bicyclo[5.3.0]dec-2-en-4-one 
O
- 
- 
- 
OD NEG NEG NEG NEG 
07.033 
1115 
2.6 Isojasmone O 3552 
167 
11050-62-7 
OD NEG NEG NEG NEG 
07.094 
1114 
2.6 3-Methyl-2-(pent-2(cis)-enyl)cyclopent-
2-en-1-one 
O 3196 
11786 
488-10-8 
OD NEG OD NEG NEG 
07.098 
1107 
2.6 3-Methylcyclohex-2-en-1-one O 3360 
11134 
1193-18-6 
OD NEG POS NEG EQU 
07.112 
1105 
2.6 3-Methyl-2-cyclopenten-1-one O 3435 
11137 
2758-18-1 
OD NEG POS NEG EQU 
07.126 
1112 
2.6 3,5,5-Trimethylcyclohex-2-en-1-one O 3553 
11918 
78-59-1 
OD NEG POS NEG EQU 
07.129 
1113 
2.6 3-Methyl-5-propylcyclohex-2-en-1-one O 3577 
 
3720-16-9 
OD NEG POS NEG EQU 
07.140 
1406 
2.6 3-Methyl-2-pentylcyclopent-2-en-1-one O 3763 
- 
1128-08-1 
OD NEG OD NEG NEG 
07.146 
380.1 
2.6 d-Carvone 
O
- 
- 
2244-16-8 
OD NEG NEG NEG NEG 
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Table 3: QSAR Predictions on Mutagenicity in Five Models for 16 Ketones from Subgroup 2.6 
FL-no 
JECFA-no 
Sub- 
group 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
ISS Local 
Model 
Ames Test 
TA100 
 
MultiCASE  
Ames test 
  
MultiCASE 
Mouse 
lymphoma test 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
MultiCASE 
Chromosoma
l aberration 
test in CHL 
07.147 
380.2 
2.6 l-Carvone 
O
- 
- 
6485-40-1 
OD NEG NEG NEG NEG 
07.172 
1110 
2.6 4-Isopropylcyclohex-2-en-1-one O 3939 
11127 
500-02-7 
OD NEG NEG NEG EQU 
07.202 
 
2.6 2,6,6-Trimethylcyclohex-2-en-1-one O - 
- 
20013-73-4 
OD NEG OD NEG NEG 
07.035 
1111 
2.6 Tetramethyl ethylcyclohexenone 
(mixture of isomers) 
OO
29 % 68 %
+
3061 
168 
17369-60-7 
OD NEG NEG NEG NEG 
07.255 
 
2.6 l-Piperitone 
O
- 
- 
4573-50-6 
OD NEG OD NEG EQU 
07.196 
- 
2.6 Pin-2-en-4-one 
O
 
11186 
80-57-9 
OD NEG POS NEG POS 
07.175 2.6 p-Menth-1-en-3-one 
O
2910 
2052 
89-81-6 
OD NEG POS NEG  OD 
Column 2: Structure group 2.6: alpha,beta-unsaturated alicyclic ketones.  
Column 6: Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD: Out of domain). 
Column 7: MultiCASE Ames test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 8: MultiCASE Mouse lymphoma test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 9: MultiCASE Chromosomal aberration in CHO (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 10: MultiCASE Chromosomal aberration in CHL (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
OD, out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physicochemical, structural, biological, etc. 
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TABLE 4: CARCINOGENICITY STUDIES 
Table 4: Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration Results Reference Comments* 
3,5,5-Trimethylcyclohex-2-en-1-one 
[07.126] 
Rats; Male, Female 
50/sex/group 
Gavage in 
corn oil 
0 (controls), 250, or 500  
mg/kg bw/day, five times per 
week 
103 weeks Males: Increased  incidences of renal tubular cell adenomas 
and adenocarcinomas and of carcinomas of the preputial 
gland.   
Females: No carcinogenic effect. 
NTP, 1986d 
 
Valid. 
 Mice; Male, Female 
50/sex/group 
Gavage in 
corn oil 
0 (controls), 250, or 500 mg/kg 
bw/day, five times per week  
103 weeks Males: Increased  incidences of hepatocellular adenomas 
and carcinomas, mesenchymal tumors in the integumentary 
system, and malignant lymphomas. 
Females: No carcinogenic effect. 
NTP, 1986d 
 
Valid. 
d-Carvone [07.146] Mice; Male, Female 
50/sex/group 
Gavage 0,  375 or 750 mg/kg bw/day,  
five times per week 
103 weeks Males and females: No increases in tumour incidences.  NTP, 1990b 
 
Valid. 
*  Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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TABLE 5: GENOTOXICITY (IN VITRO) 
Table 5: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Reported 
Result  
Reference  Comments e
Tetramethyl ethylcyclohexenone 
(mixture of isomers [07.035] 
Reverse mutation S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
 5 concentrations up to 
cytotoxicity,  or max. 3600 
µg/plate 
Negativea Wild et al., 1983 Limited validity (no TA 102 or E. 
Coli); possibly slightly low  maximal 
concentration tested. 
3,5,5-Trimethylcyclohex-2-en-1-one 
[07.126] 
Reverse mutation S. typhimurium TA97, TA98, TA100, 
TA1535, TA1537 
33–10 000 microg/plate Negativea Mortelmans et al., 1986 Valid. 
Mutation S. typhimurium TA98, TA100, TA1535, 
TA1537 
33–10 000 microg/plate Negativea NTP, 1986d NTP study carried out according to 
standard US-EPA guideline; result is 
considered as valid. 
Mutation L5178YTk+/– mouse lymphoma cells 67–810 microg/ml Negativeb McKee et al., 1987 Validity cannot be evaluated (tested 
with S9; abstract only with very 
limitred information). 
Mutation L5178YTk+/– mouse lymphoma cells 130–1300 microg/ml Negativec McKee et al., 1987 Validity cannot be evaluted (tested 
without S9; abstract only with very 
limitred information). 
Mutation L5178YTk+/– mouse lymphoma cells 0.089–0.89 microl/ml Negativec O’Donoghue et al., 1988 Valid according to current guidelines. 
Mutation L5178YTk+/– mouse lymphoma cells 0.13–1.3 microl/ml Negativeb  O’Donoghue et al., 1988 Valid according to current guidelines. 
Mutation L5178YTk+/– mouse lymphoma cells 1200 microg/ml Positiveb NTP, 1986d NTP study carried out according to 
standard US-EPA guideline; Not tested 
with S9. Result is considered as valid. 
Mutation L5178YTk+/– mouse lymphoma cells Not reported (however, up to 
cytotoxic concentrations) for 3 
hr exposure.  
Negativea Honma et al., 1999a Limited validity since data were 
presented in a summarized Table 
format only (as a result of an 
international collaborative study). 
Mutation L5178YTk+/– mouse lymphoma cells Up to 1500 microg/ml Positiveb
 
Honma et al., 1999b Limited validity since mutation 
frequencies were not reported in Table 
format. Tested only in the absence of 
S9. Isophorone was mutagenic after 24 
hr treatments in the absence of S9. 
Although only graphs are plotted, it 
seems that increases in MF that 
exceeded the Global Evaluation Factor 
occurred at around 1250‐1500 μg/ml 
where toxicity (by relative survival) 
reached 70-90 %. 
Chromosomal aberration Chinese hamster ovary cells 5–1600 microg/ml Negativea Gulati et al., 1989 Limited validity (not clear if gaps were 
included in the scores). 
Chromosomal aberration Chinese hamster ovary cells 250–1600 microg/ml Negativea NTP, 1986d NTP study carried out according to 
standard US-EPA guideline; result is 
considered as valid. 
Chromosomal aberration  Chinese hamster lung fibroblasts  0-1250b μg/ml  
0 – 1500c μg/ml 
 
Positivea Matsuoka et al., 1996 Valid. 
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Table 5: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Reported 
Result  
Reference  Comments e
Chromosomal aberration  Chinese hamster lung fibroblasts  250–1000 mg/ml Negativea Matsuoka et al., 1996 Valid. Exposed to isophorone without 
metabolic activation for 24 hrs or 48 
hours, cytotoxic at highest 
concentrations. 
Sister chromatid exchange Chinese hamster ovary cells 5–1600 mg/ml Positiveb,d  Gulati et al., 1989 Valid (pos – S9; neg + S9). 
Sister chromatid exchange Chinese hamster ovary cells 160–1000 mg/ml Negativea NTP, 1986d Valid. NTP study carried out according 
to Standard US-EPA guideline; result 
is considered as valid. 
Unscheduled DNA synthesis Rat hepatocytes 0.005–0.4 µl/ml Negative O’Donoghue et al., 1988 Valid according to current guidelines 
Unscheduled DNA synthesis Rat hepatocytes 5 - 200 μl/ml Negativea McKee et al., 1987 Validity cannot be evaluated (abstract 
only with very limited information). 
Carvone (isomer not specified) Gene mutation S. typhimurium TA1535, TA1537, TA98, 
TA100 
3 µmol/plate Negative Florin et al., 1980 Insufficient validity (spot test, not 
according to OECD guideline, methods 
and results insufficiently reported). 
Isomer (D or L) not reported. 
Rec assay  Bacillus subtilis H17 (rec+) and M45 (rec-
) 
0.6 ml/disc Negative Matsui et al., 1989 The test system used is considered 
inappropriate.  
d-Carvone [07.146] Gene mutation S. typhimurium TA1535, TA98, TA100, 
TA1537 
333 µg/plate Negativea NTP, 1990b Valid. 
Gene mutation 
(preincubation) 
S. typhimurium TA1535, TA98, TA100, 
TA1537 
560 µg/plate Negative Mortelmans et al., 1986 Valid. 
Sister chromatid exchange Chinese hamster ovary cells 502 µg/ml Positivea NTP, 1990b Valid. 
Chromosomal aberration Chinese hamster ovary cells 400 µg/ml Positivea NTP, 1990b Valid. 
a: With and without metabolic activation. 
b: Without metabolic activation. 
c:  With metabolic activation. 
d: Cytotoxic at next highest dose tested (1600 mg/ml). 
e: Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate  test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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TABLE 6: GENOTOXICITY (IN VIVO) 
 
Table 6: GENOTOXICITY (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments a
Tetramethyl ethylcyclohexenone 
(mixture of isomers [07.035] 
Sex-linked recessive lethal 
mutation 
D. melanogaster Feed  10 mM Negative Wild et al., 1983 Limited validity (low nr of chromosomes, limited 
reporting). 
Micronucleus formation Mouse bone marrow i.p. 180, 307, 450 mg/kg bw Negative Wild et al., 1983 Limited validity. Only analysis at one time point; 
no PCE/NCE ratio reported. 
3,5,5-Trimethylcyclohex-2-en-1-
one [07.126] 
 
 
Sex-linked recessive lethal 
mutation 
D. melanogaster  2000b  and 12500c  ppm Negative Foureman et al., 1994 Valid, however, only limited relevance. 
Micronucleus formation CD-1 mice i.p. 540 mg/kg bw (MTD) Negative McKee et al., 1987 Validity cannot be evaluated. Abstract only; very 
limited information nodata  on PCE/NCE ratio. 
Micronucleus formation CD-1 mice i.p. 0.54 ml/kg bw Negative O’Donoghue et al., 1988 Limited validity. Only one dose level tested, this 
dose level corresponded to the LD20; sample 
schedule inadequate. 
Chromosomal aberration B6C3F1 mice i.p. 125, 250, 500 mg/kg bw Negative NTP-Website Valid. Submitted by Industry in 2009. The 
standard protocol for in vivo CA is not given on 
the NTP website. However, based on Shelby and 
Witt (1995), animals should have been sampled at 
17 hr and, if negative, also at 36 hr. The data on 
the NTP website are only for bone marrow 
sampled at 36 hr. It is therefore possible that a 17 
hr sample was also taken, and found to be 
negative, but the data not posted. Fifty cells per 
animal were scored for CA and no increases in CA 
were seen. No measures of toxicity were recorded, 
but i.p. dosing should have guaranteed systemic 
exposure. 
DNA binding F344 rats Gavage 500 mg unlabelled isophorone/kg 
bw spiked with 14C-isophorone 
(0.4 mCi/rat) 
Negative Thier et al., 1990 Limited validity. Submitted by Industry in 2009. 
No positive controls and no untreated controls 
used. Liver and kidney were analysed. 
DNA binding B6C3F1 mice Gavage 500 mg unlabelled isophorone/kg 
bw spiked with 14C-isophorone 
(0.08 mCi/mouse) 
Negative Thier et al., 1990 Limited validity. Submitted by Industry in 2009. 
No positive controls and no untreated controls 
used. Liver and kidney were analysed. 
DNA binding F344 rats (10 males) Gavage 500 mg/kg bw 14C-isophorone 
(0.1 mCi/rat) 
Negative Morishita et al., 1997 Valid. Preputial glands and kidneys were analysed. 
DNA adducts (32P-
Postlabelling) 
F344 rats (7 males and 7 
females per dose group) 
Gavage 0 and 500 mg/kg/day for 5 days. Negative Morishita et al., 1997 Valid. Preputial glands were analysed. 
a: Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate  test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
b: Oral administration. 
c: Injection. 
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 ABBREVIATIONS 
BW  Body Weight 
CAS  Chemical Abstract Service 
CHL  Chinese hamster lung cell(s) 
CHO  Chinese hamster ovary cell(s) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
DTU-NFI Danish Technical University – National Food Institute 
EC  European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS Flavour Information System database 
ID  Identity 
IP  Intraperitoneal 
IR  Infrared spectroscopy 
ISS  Istituto Superiore di Sanita 
JECFA The Joint FAO/WHO Expert Committee on Food Additives 
MS  Mass spectrometry 
MSDI  Maximum Survey-derived Daily Intake 
NMR  Nuclear magnetic resonance 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Programme 
OECD  Organisation for Economic Co-operation and Development 
PCE/NCE Polychromatic erythrocytes/normochromatic erythrocytes 
(Q)SAR (Quantitative) structure-activity relationship 
SCE  Sister chromatid exchange 
SCF  Scientific Committee on Food 
UDS  Unscheduled DNA synthesis 
US EPA United States Environmental Protection Agency 
WHO  World Health Organisation 
 
 
